Cabaletta Bio [CABA] Initiated At Buy by Chardan Capital
Chardan Capital launched its Cabaletta Bio [CABA] rating to the equivalent of Buy and assigned the price target of $21.0, in a research note dated 2021-01-08. That figure represents around a 60.67% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Morgan Stanley’s analysts assigning the shares […]